Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RBBP8
REST API REST API
Homo sapiens
RBBP8 is differentially expressed in 277 experiments: 125 organism parts: kidney, mammary gland, ... (123 more);, 182 disease states: normal, glioblastoma, ... (180 more);, 96 cell types 364 cell lines 40 compound treatments and 68 other conditions.
Synonyms RIM, CtIP
Orthologs RBBP8 (Gallus gallus)   RBBP8 (Bos taurus)   RBBP8 (Danio rerio)   ENSCING00000004242 (Ciona intestinalis)   Rbbp8 (Mus musculus)   Rbbp8 (Rattus norvegicus)   RBBP8 (Xenopus laevis)   RBBP8 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, DNA repair, damaged DNA binding, meiosis, G1/S transition of mitotic cell cycle, nucleus, hydrolase activity, endonuclease activity, cell cycle checkpoint, regulation of transcription from RNA polymerase II promoter, DNA double-strand break processing involved in repair via single-strand annealing, blastocyst hatching, single-stranded DNA specific endodeoxyribonuclease activity
InterPro Term DNA-repair_Sae2/CtIP, CtIP_N
UniProt Accession Q99708, A8MTZ9, A6NKN2, E7ETY1
Search EB-eye ENSG00000101773
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (36 experiments)

Factor Value U/D Experiments
BT474
2
E-MTAB-37, E-MEXP-440
MCF7
2
E-MTAB-37, E-GEOD-5258
A549
2
E-GEOD-3202, E-GEOD-6013
MCF-7
2
E-GEOD-20081, E-GEOD-19639
MDA468
2
E-MEXP-440, E-MTAB-62
SW480
2
E-MEXP-1014, E-MTAB-37
358 more value(s).


Cell type

studied in E-GEOD-21668, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, ... (49 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-TABM-145, E-MTAB-25
2
E-TABM-130, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
stromal cell
1
2
E-MEXP-2034, E-GEOD-10797, E-GEOD-1460
90 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-25, E-GEOD-2466, E-MEXP-2069, ... (48 experiments)

Factor Value U/D Experiments
breast carcinoma
2
E-GEOD-7307, E-MTAB-37
Classic-KS, HIV-, nodular (late) stage
2
E-MEXP-66, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-96
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
control
1
2
E-GEOD-21912, E-GEOD-16363, E-GEOD-20602
176 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-5741, E-GEOD-3720, E-GEOD-5824, E-MEXP-1958, ... (25 experiments)

Factor Value U/D Experiments
none
4
6
E-GEOD-4668, E-GEOD-5824, E-MEXP-1601, E-GEOD-20719, E-GEOD-412, ... (10 experiments)
baseline sevoflurane
1
E-GEOD-4386
glutamine
1
E-MEXP-941
5-fluorouridine
1
E-GEOD-995
5-aza-2'-deoxycytidine
2
1
E-GEOD-5230
Cxcl12
1
E-GEOD-7307
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-MTAB-37, E-MEXP-1251, E-GEOD-1563, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-MEXP-958, ... (6 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-TABM-147, E-GEOD-21887 ... (5 experiments)

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (9 experiments)

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-TABM-36, E-GEOD-2466, E-GEOD-17476, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-TABM-440, E-GEOD-1692, ... (13 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-GEOD-10433, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-19703, E-GEOD-1460, E-GEOD-2487, E-MEXP-1403

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561

Vehicle
studied in E-GEOD-5258

Processing time: 0.305 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM